March 15, 2018 | Yokneam-based Israeli startup PixCell, which develops, manufactures, and markets portable medical diagnostic products for simple blood sampling and analysis, announced that it was awarded a 2.5 million Euro (approximately $3 million) grant to “accelerate commercialization of its product the HemoScreen.” The funding will serve to further test the product, the company said. The Hemoscreen is a portable blood analyzer that performs common test including a blood count with results within 5 minutes, PixCell says. The product is CE marked and expected to be FDA cleared during 2018.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments